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Echocardiography
ElectrocardiographyHypertrophic cardiomyopathy (HCM) is a common genetic
cardiac disorder that causes distinctive anatomic and histologic
features aswell as awide array of clinicalmanifestations [1]. HCM is
the most frequent cause of sudden cardiac death in young athletes
[2]. Morphologic features of HCM include ventricular hypertrophy
that is usually asymmetric and particularly involves the interven-
tricular septum. Epidemiologic data indicate that 2 in 1000 young
adults have unexplained hypertrophy [2]. Mutations in genes that
encode sarcomereproteins includingcardiacmyosinbindingprotein
C gene (MYBPC3), cardiac troponinT gene (TNNT2), cardiac troponin I
gene (TNNI3), and cardiac beta-myosin heavy chain gene (MYH7) are
well-established causes of the disease [1,3]. Studies in populations
with familial HCM often reported that mutations in sarcomere
proteins could bedetected in around50%of the study subjects [3–5].
Left ventricular systolic dysfunction is a recognized part of HCM,
and sometimes it is called as end stage (deﬁned as left ventricular
ejection fraction<50% at rest) [6,7]. It is reported that subjects with
HCM caused by mutations in TNNI3 and TNNT2 start to develop left
ventricular systolic dysfunction at around 40 years of age [8,9]. In a
relatively large population with mutations in various sarcomeric
genes, non-MYBPC3 mutation carriers developed left ventricular
systolic dysfunction more frequently than MYBPC3 mutation
carriers, and the majority of the sarcomere gene mutation carriers
with systolic dysfunction had fatal outcomes during follow-up [1].
On the other hand, left ventricular apical aneurysm (LVAA) is an
underrecognized subgroup of HCM [10]. LVAA was deﬁned as a
discrete thin-walled dyskinetic or akinetic segment of the most
distal portion of the chamberwith a relatively wide communication
to the LV cavity. Previous descriptions of HCM patients with LVAA
have been based largely on case reports or small patient series [11].
Consequently, this subgroup of patients has remained underappre-
ciated, and its clinical proﬁle and natural history are largelyDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.02.011
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large HCM patient cohort, the expression of this subset of patients
with respect to prevalence and clinical course in the USA. Although
there has been limited information focusing on LVAA in HCM in
Japan, Ichidaetal. [12] carriedout retrospective surveillanceofLVAA
in a single center analysis of a population of 247 HCM patients.
Prevalence of LVAA and systolic dysfunction in HCM patients
InRef. [12], the prevalenceof LVAA inHCMpatientswas reported
to be 21 out of 247 (8.5%), which is higher than the reports from the
USA [28 out of 1299 (2.2%)], as stated in Ref. [10]. Ichida et al. [12]
speculated that the subgroup of LVAA in the USA was underappre-
ciated, and that apical aneurysms are not rare in Japanese patients
with HCM. Nakamura et al. [13] reported that in Japan 15% of HCM
patients showed segmental wall motion abnormalities including
apical aneurysms.
The prevalence of left ventricular systolic dysfunction (deﬁned as
left ventricular ejection fraction <50% at rest) was reported to be
44 of 1259 (3.5%) in Western countries [7]. In the report, 11 of
the 44 patients (25%) had systolic dysfunction at initial evaluation;
the other 33 patients (75%) developed systolic dysfunction
during follow-up. The study included 1259 consecutively enrolled
HCM patients who were analyzed retrospectively at three centers:
MinneapolisHeart Institute Foundation,Minneapolis, USA (n = 752);
EnteOspedalieroOspedali Galliera, Genoa, Italy (n = 354); and Tufts-
New England Medical Center, Boston, USA (n = 153). In Japan, we
surveyed systolic dysfunction in 157 genotyped HCM patients, and
the prevalencewas 21 of 157 (13.4%), which was higher than that of
Western countries.We speculate that thiswas becauseour 157HCM
patients in Japan [1] did not include somany patientswith relatively
mild phenotype compared to the 1259 patients from the three
centers [7]. During follow-up, incidence of systolic dysfunction was
similar: 1.12 cases per 100 person-years in Western countries and
1.60 cases per 100 person-years in Japan.
Clinical course of LVAA and systolic dysfunction in HCM
patients
In the study by Ichida et al. [12], over the follow-up period of
4.7  3.3 years, 10 (47.6%) of the 21 HCM patients with LVAA
experienced adverse clinical events, including appropriate implant-
able cardioverter-deﬁbrillator (ICD) implantation for ventricular
tachycardia/ventricular ﬁbrillation (n = 5), non-fatal thromboembolicss under CC BY-NC-ND license.
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Fig. 1. Event-free survival in total cardiovascular events with Cox proportional hazards regression analysis (adjusted for age and sex). (A) All hypertrophic cardiomyopathy
(blue line) and group H (green line). (B) Groups G (blue line) and H (green line). (C) Groups NG (blue line) and H (green line). Group G = hypertrophic cardiomyopathy with
sarcomere gene mutations; Group H = hypertensive heart disease; Group NG = hypertrophic cardiomyopathy without sarcomere gene mutations. CI = conﬁdence interval.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
Reproduced, with permission, from Fujita et al. [15].
Editorial / Journal of Cardiology 64 (2014) 253–255254stroke (n = 4), and syncope (n = 2). Two patients also developed
systolic dysfunction. No sudden cardiac death or progressive heart
failure was detected. The annual adverse cardiovascular event rate
was 10.1%/year. The HCM patients with large LVAA (>2 cm)
were more likely to experience an adverse disease complication
(8 of 13, 62%) than the patients with small aneurysms (<2 cm; 2 of
8, 25%).
In the study by Maron et al. [10] in the USA, over the follow-up
period of 4.1  3.7 years, 12 patients (42.9%) of the 28 HCM patients
with LVAA experienced an adverse clinical event, including sudden
cardiac death (n = 2), aborted cardiac arrest (n = 2), appropriate ICD
intervention for ventricular tachycardia/ventricular ﬁbrillation
(n = 3), and progressive heart failure with increase of 1 New York
Heart Association class and/or death (n = 5). Annual HCM-related
adverse cardiovascular event rate was 10.5%/year. Six of these 12
patients also developed systolic dysfunction. HCMpatients with large
LVAAweremore likely to experience an adverse disease complication
(5 of 6, 83%) than patients with medium or small aneurysms (7 of
22, 32%). Speciﬁc disease complications were more common in
association with large or medium compared with small aneurysms,
i.e. sudden death events, left ventricular systolic dysfunction,
progressive heart failure symptoms, and embolic stroke/left ventric-
ular apical thrombus.
In these two studies, the follow-up period and the annual
adverse cardiovascular event rate were similar, 4.7  3.3 years and
10.1%/year in the study from Japan and 4.1  3.7 years and 10.5%/year
in the study from the USA, respectively. This information is helpful in
themanagement of HCM, especially in HCMpatientswith LVAA.With
this condition, systolic dysfunction occurred in 2 of the 10 patients
with adverse clinical events in Japan, and in 6 of the 12 patients with
adverse clinical events in the USA. From the viewpoint of systolic
dysfunction in HCM, the prognosis is poor. The interval from
identiﬁcation of systolic dysfunction to death or transplantation
was relatively brief (2.7  2.4 years) in Western countries [7]. In our
Japanese report [1], after the onset of systolic dysfunction, 11 of the
12 subjects died during a mean follow-up of 8.3 years.
Identiﬁcation of LVAA in HCM patients
In the study by Maron et al. [10] in the USA, 28 were identiﬁed
with LVAA; however, apical aneurysms were recognized by
echocardiography in only 16 of the 28 patients (57%), but by
cardiovascular magnetic resonance in the 12 patients undetected
by echocardiography. The authors emphasized that they oftenrequire cardiovascular magnetic resonance for identiﬁcation of
LVAA. In contrast, Ichida et al. [12] detected all 21 HCM patients
with LVAA by echocardiography. The authors emphasized the
importance of serial electrocardiography. For the identiﬁcation of
LVAA in HCM patients, the sensitivity of ST-segment elevation in
lead V3 through V5 of electrocardiography was 66.7% and the
speciﬁcity of that was 98.7%.
Summary
The present study by Ichida et al. [12] reported the prevalence
and clinical course of an underrecognized subgroup of HCM
patients with LVAA. Various modules, such as serial electrocardi-
ography, echocardiography, and cardiovascular magnetic reso-
nance are required to detect and follow the HCM patients with
LVAA. Recently, genetic analysis has been performed in several
genetic cardiovascular disorders [14]. The genetic information will
be helpful to predict the clinical course of HCMpatients (Fig. 1) [15]
with LVAA in the future as shown in HCM patients with systolic
dysfunction [1]. As there has not been a comprehensive report
examining the detailed clinical course of HCM patients with LVAA
in Japan, the present study provides important information on this
issue. The accumulation of these clinical and genetic data will be
essential for the better management of HCM patients with LVAA.
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